Arylcyclohexylamines

Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results

Retrieved on: 
Friday, July 30, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, General anesthetics, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Therapy, Bipolar disorder, Mental health

Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry.

Key Points: 
  • Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry.
  • Braxia Health is the first to offer novel Ketamine therapy, including intravenous therapy, to patients in a private clinical setting in Quebec.
  • In June 2021, the Company announced that Chief Medical and Scientific Officer Dr. Joshua Rosenblat, will initiate a first-of-its-kind ketamine clinical trial to treat bipolar depression.
  • "Braxia Scientific has achieved significant milestones to date, and we are picking up the pace," noted CEO Dr. Roger McIntyre.

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Patent

The Companys intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.

Key Points: 
  • The Companys intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.
  • I am pleased with our continued dedication to becoming a leader of novel ketamine products and implementing a patent strategy that would protect our clinical development and commercialization initiatives.
  • The patent application, entitled Methods and Compositions of Ketamine Formulation for Intradermal Administration, describes the potential improvement and therapeutic value of ketamine by delivering it through the skin.
  • PharmaTher is positioning itself as an innovator of novel uses, formulations and delivery forms of ketamine.

Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami

Retrieved on: 
Friday, July 9, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, Wellness, Tristar, Clinical trial

Tristar Wellness is an upscale Miami Beach Florida based medical facility with an experienced team of doctors focused on implementing the latest in medical technology and research.

Key Points: 
  • Tristar Wellness is an upscale Miami Beach Florida based medical facility with an experienced team of doctors focused on implementing the latest in medical technology and research.
  • Dane Jackman, Managing Director of Tristar Wellness, said, This partnership marks the first in a line of Ketamine related micro-trials slated at Tristar Wellness, Miami Beach.
  • Ehave Chief Executive Officer, Ben Kaplan, said, "Hiring an IRB is a very important step in our ketamine clinical Trials in Miami with Tristar Wellness.
  • The safety of the individuals participating in our trials is of utmost importance to both Ehave and Tristar Wellness.

Ketamine One Announces Adam Deffett as Interim CEO

Retrieved on: 
Wednesday, July 7, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Ketamine, Ketones, Sedatives

Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO.

Key Points: 
  • Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO.
  • Ketamine One has launched on a search process to identify appropriate candidates and ultimately hire a permanent CEO to lead the Company, which it expects to complete in the coming months.
  • I would like to thank Robert for stewarding the transition of the Company from an investment issuer under the name of Myconic Capital Corp. to a company dedicated to mental healthcare and the rebrand to Ketamine One, said Adam Deffett, Interim CEO of Ketamine One.
  • Adam Deffett is a senior capital markets professional with over 15 years of experience in the Canadian equity markets.

Leading Psychedelic Wellness Company Delic Completes Acquisition of Ketamine Infusion Centers LLC, Adding Health Clinic Chain to Portfolio

Retrieved on: 
Tuesday, July 6, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Dissociative drugs, Ketones, Nicotinic antagonists, Sedatives, Ketamine, OTC Markets Group, WellPet, Delić

VANCOUVER, BC, July 6, 2021 /PRNewswire/ -Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketamine Infusion Centers LLC ("KIC").

Key Points: 
  • VANCOUVER, BC, July 6, 2021 /PRNewswire/ -Delic Holdings, Inc. ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform has completed its acquisition (the "Acquisition") of Ketamine Infusion Centers LLC ("KIC").
  • KIC will be strategically positioned to leverage DELIC platform and brand: DELIC expects to drive patients to KIC through its media platform and become a national leader
    Established history of providing ketamine infusion services.
  • "The DELIC team is committed to making psychedelic wellness accessible to the masses and with this chain of clinics we are making that vision possible."
  • DELIC is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

Ketamine One Highlights Psychedelic Research and Announces New Clinical Trial

Retrieved on: 
Thursday, June 17, 2021
Psychoactive drugs, Drugs, Health sciences, Drug discovery, Antidepressants, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Ketamine, Psychedelic therapy, Clinical trial, Clinical

KGK is rapidly being integrated into Ketamine Ones mental health platform, accelerating the ability to foster value creation through the Companys clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work.

Key Points: 
  • KGK is rapidly being integrated into Ketamine Ones mental health platform, accelerating the ability to foster value creation through the Companys clinic portfolio, grow its work with existing third-party clients and establish a leadership position in psychedelic research and clinical trial work.
  • Being at the forefront of psychedelics research strongly positions Ketamine One and KGK to generate defendable intellectual property and secure first mover advantages.
  • Further, the Company is pleased to report that KGK has recently been awarded a new clinical trial contract, a research project and has also completed two studies.
  • Developing a network of vertically-integrated clinics within Ketamine One for the conduct of psychedelic clinical trials.

Ketamine One Closes Previously Announced Acquisition of Integrated Rehab and Performance

Retrieved on: 
Tuesday, June 15, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Antidepressants, Chloroarenes, Nicotinic antagonists, General anesthetics, Ketamine

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (Ketamine One or the Company) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has closed its previously announced acquisition (the Acquisition) of Integrated Rehab and Performance Ltd. (IRP).

Key Points: 
  • VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (Ketamine One or the Company) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has closed its previously announced acquisition (the Acquisition) of Integrated Rehab and Performance Ltd. (IRP).
  • As consideration for the Transaction, Ketamine One issued 602,410 common shares of the Company (the Consideration Shares) at a price per common share of $1.66.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Ketamine One Appoints Loreto Grimaldi to Board of Directors

Retrieved on: 
Monday, June 14, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, General anesthetics, Sedatives, Ketamine, Loreto, Baja California Sur, Olney's lesions, Loreto

Mr. Grimaldi brings over 25 years of corporate, transactional and governance experience to Ketamine One.

Key Points: 
  • Mr. Grimaldi brings over 25 years of corporate, transactional and governance experience to Ketamine One.
  • On behalf of the Company, I extend a warm welcome Loreto as the newest member of Ketamine Ones Board of Directors, said Rob Meister, Chief Executive Officer of Ketamine One.
  • Loreto is also the co-founder of Untether Capital Inc. dba Fleets Coffee, which is a disruptive food technology platform.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

ESO Publishes Peer-Reviewed Paper On Prehospital Ketamine Use At A National Level

Retrieved on: 
Friday, June 11, 2021
Research, Technology, Hospitals, Software, Practice Management, Other Health, Pharmaceutical, Health, Data management, Science, Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, European Southern Observatory, ESO, the Ketamine Research, ESO, THE KETAMINE RESEARCH, ESO

The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.

Key Points: 
  • The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.
  • View the full release here: https://www.businesswire.com/news/home/20210611005060/en/
    The ketamine conversation has reached a national, mainstream audience, said Dr. Brent Myers, Chief Medical Officer for ESO.
  • EMS Ketamine Administrations: Based on data from the ESO Data Collaborative, EMS administered ketamine to 11,291 patients from January 1, 2019-December 31, 2019.
  • ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.

Ketamine One Launches Immersive Virtual Reality R&D Program at MindScape Clinic

Retrieved on: 
Monday, June 7, 2021
Psychiatry, Psychoactive drugs, Psychiatric diagnosis, Branches of biology, Abnormal psychology, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Management of depression, Mental disorder, Obsessive–compulsive disorder

Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals.

Key Points: 
  • Clinic patients who select IVR-based treatments will receive a tailored therapy plan that includes a determination of their mental state and individual goals.
  • With over 2,000 treatments administered since inception, MindScape also recently expanded its service offering to provide spa-like therapeutic treatment experiences.
  • Mindscape Ketamine & Infusions Therapy, PLLC is a clinic in Houston, Texas, offering affordable delivery of concierge IV ketamine therapy for treatment-resistant mood disorders, mental health disorders, and chronic pain conditions.
  • Mindscape Ketamine & Infusion Therapy, PLLC is the only IV ketamine clinic in Houston to offer virtual reality-based guided meditation to complement IV ketamine infusions in the treatment of depression, bipolar disorder, anxiety, PTSD, OCD, and other mood disorders.